Compare CRAI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRAI | PHAR |
|---|---|---|
| Founded | 1965 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.0M | 885.7M |
| IPO Year | 1998 | 2020 |
| Metric | CRAI | PHAR |
|---|---|---|
| Price | $149.08 | $12.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $245.00 | $38.33 |
| AVG Volume (30 Days) | ★ 118.2K | 9.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ 20.77 | N/A |
| EPS | ★ 8.14 | N/A |
| Revenue | ★ $751,583,000.00 | N/A |
| Revenue This Year | $7.82 | $10.04 |
| Revenue Next Year | $5.14 | $2.51 |
| P/E Ratio | ★ $18.24 | $3,041.22 |
| Revenue Growth | ★ 9.33 | N/A |
| 52 Week Low | $132.17 | $9.54 |
| 52 Week High | $227.29 | $21.34 |
| Indicator | CRAI | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 38.59 |
| Support Level | $142.53 | $11.84 |
| Resistance Level | $166.99 | $13.61 |
| Average True Range (ATR) | 5.87 | 0.46 |
| MACD | 0.93 | 0.09 |
| Stochastic Oscillator | 81.65 | 29.45 |
CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.